<DOC>
	<DOCNO>NCT01194973</DOCNO>
	<brief_summary>The record Primary purpose assess efficacy eculizumab adult patient aHUS control TMA characterize thrombocytopenia , hemolysis renal impairment .</brief_summary>
	<brief_title>An Open-label , Multi-center Clinical Trial Eculizumab Adult Patients With Atypical Hemolytic-uremic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>Inclusion : 1 . Patient must willing able give write informed consent . 2 . Patient 's age &gt; 18 year . 3 . Patients exhibit thrombocytopenia , hemolysis elevate Serum Creatinine . 4 . Patients diagnosis aHUS without identify complement regulatory protein genetic abnormality anticomplement factor antibody etiologies hemolytic uremic syndrome rule confirm exclusion criterion 5 . Female patient childbearing potential must practice effective , reliable medically approve contraceptive regimen entire duration study , include followup period . At time last followup visit , patient must agree continue use adequate contraception method 5 month follow discontinuation eculizumab treatment . 6 . Able willing comply study procedure Exclusion : 1 . Chronic dialysis . 2 . Prior eculizumab use hypersensitivity eculizumab , murine proteins one excipients . 3 . Known familial ADAMTS13 deficiency ( ADAMTS13 &lt; 5 % ) . 4 . Typical HUS ( know Shiga toxin + ) . 5 . History malignancy within 5 year screen . 6 . Known human immunodeficiency virus ( HIV ) infection . 7 . Identified drug exposurerelated HUS . 8 . Infectionrelated HUS . 9 . HUS relate bone marrow transplant ( BMT ) . 10 . HUS related vitamin B12 deficiency . 11 . Known Systemic Lupus Erythematosus ( SLE ) antiphospholipid antibody positivity syndrome . 12 . Patients confirm diagnosis sepsis define positive blood culture within 7 day screen visit treat antibiotic organism sensitive . 13 . Presence suspicion active untreated systemic bacterial infection , opinion Investigator confound accurate diagnosis aHUS impedes ability manage aHUS disease . 14 . Pregnancy lactation . 15 . Unresolved systemic meningococcal disease . 16 . Any medical psychological condition , opinion investigator , could increase patient 's risk participate study confound outcome study . 17 . Patients receive chronic intravenous immunoglobulin ( IVIg ) within 8 week chronic Rituximab therapy within 12 week screen visit . 18 . Patients receive immunosuppressive therapy steroid , mTOR inhibitor , calcineurin inhibitor ( e.g. , cyclosporine tacrolimus ) exclude unless : [ 1 ] part establish posttransplant antirejection regime , [ 2 ] patient confirm antiComplement Factor Antibodies require immunosuppressive therapy , [ 3 ] steroid use condition aHUS ( example asthma ) . 19 . Participation investigational drug trial device trial , procedures begin 4 week prior screen throughout entire trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Atypical Hemolytic-Uremic Syndrome</keyword>
</DOC>